Research ExplorerPublicationsImpact of the CYP2D6 genotype on the clinical effects of met...

Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.

Standard

Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. / Rau, Thomas; Wuttke, H; Michels, L M; Werner, U; Bergmann, K; Kreft, M; Fromm, M F; Eschenhagen, Thomas.

In: CLIN PHARMACOL THER, Vol. 85, No. 3, 3, 01.03.2009, p. 269-272.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rau, T, Wuttke, H, Michels, LM, Werner, U, Bergmann, K, Kreft, M, Fromm, MF & Eschenhagen, T 2009, 'Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.', CLIN PHARMACOL THER, vol. 85, no. 3, 3, pp. 269-272. https://doi.org/10.1038/clpt.2008.218

APA

Rau, T., Wuttke, H., Michels, L. M., Werner, U., Bergmann, K., Kreft, M., Fromm, M. F., & Eschenhagen, T. (2009). Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. CLIN PHARMACOL THER, 85(3), 269-272. [3]. https://doi.org/10.1038/clpt.2008.218

Vancouver

Rau T, Wuttke H, Michels LM, Werner U, Bergmann K, Kreft M et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. CLIN PHARMACOL THER. 2009 Mar 1;85(3):269-272. 3. https://doi.org/10.1038/clpt.2008.218

Bibtex

@article{6e9b44f67f954b689e10b2a04b0823f6,
title = "Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.",
abstract = "After administration of metoprolol, plasma concentrations of the drug are markedly higher in CYP2D6 poor metabolizers (PMs) than in non-PMs. In a prospective double-blind 3-month study, we investigated whether this translates into differences in metoprolol's effects after initiation of therapy. Despite administering equal doses to PMs and non-PMs, metoprolol plasma concentrations were 4.9-fold higher in the PM group. Metoprolol evoked significantly and persistently greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure in PMs than in non-PMs. It appears, therefore, that the CYP2D6 genotype contributes to interindividual differences in metoprolol response.",
keywords = "Adult, Aged, Blood Pressure, Cytochrome P-450 CYP2D6, Double-Blind Method, Female, Genotype, Heart Rate, Humans, Longitudinal Studies, Male, Metoprolol, Middle Aged, Polymorphism, Genetic, Prospective Studies",
author = "Thomas Rau and H Wuttke and Michels, {L M} and U Werner and K Bergmann and M Kreft and Fromm, {M F} and Thomas Eschenhagen",
year = "2009",
month = mar,
day = "1",
doi = "10.1038/clpt.2008.218",
language = "English",
volume = "85",
pages = "269--272",
journal = "CLIN PHARMACOL THER",
issn = "0009-9236",
publisher = "NATURE PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.

AU - Rau, Thomas

AU - Wuttke, H

AU - Michels, L M

AU - Werner, U

AU - Bergmann, K

AU - Kreft, M

AU - Fromm, M F

AU - Eschenhagen, Thomas

PY - 2009/3/1

Y1 - 2009/3/1

N2 - After administration of metoprolol, plasma concentrations of the drug are markedly higher in CYP2D6 poor metabolizers (PMs) than in non-PMs. In a prospective double-blind 3-month study, we investigated whether this translates into differences in metoprolol's effects after initiation of therapy. Despite administering equal doses to PMs and non-PMs, metoprolol plasma concentrations were 4.9-fold higher in the PM group. Metoprolol evoked significantly and persistently greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure in PMs than in non-PMs. It appears, therefore, that the CYP2D6 genotype contributes to interindividual differences in metoprolol response.

AB - After administration of metoprolol, plasma concentrations of the drug are markedly higher in CYP2D6 poor metabolizers (PMs) than in non-PMs. In a prospective double-blind 3-month study, we investigated whether this translates into differences in metoprolol's effects after initiation of therapy. Despite administering equal doses to PMs and non-PMs, metoprolol plasma concentrations were 4.9-fold higher in the PM group. Metoprolol evoked significantly and persistently greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure in PMs than in non-PMs. It appears, therefore, that the CYP2D6 genotype contributes to interindividual differences in metoprolol response.

KW - Adult

KW - Aged

KW - Blood Pressure

KW - Cytochrome P-450 CYP2D6

KW - Double-Blind Method

KW - Female

KW - Genotype

KW - Heart Rate

KW - Humans

KW - Longitudinal Studies

KW - Male

KW - Metoprolol

KW - Middle Aged

KW - Polymorphism, Genetic

KW - Prospective Studies

U2 - 10.1038/clpt.2008.218

DO - 10.1038/clpt.2008.218

M3 - SCORING: Journal article

C2 - 19037197

VL - 85

SP - 269

EP - 272

JO - CLIN PHARMACOL THER

JF - CLIN PHARMACOL THER

SN - 0009-9236

IS - 3

M1 - 3

ER -